Preoperative albumin-bilirubin score predicts short-term outcomes and long-term prognosis in colorectal cancer patients undergoing radical surgery

doi:10.4240/wjgs.v16.i7.2096

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (119)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

WORD

HTML

Figures (1-3)

Tables (1-5)

Sum=86

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=27

Jul 27, 2024 (publication date) through Jul 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. Jul 27, 2024; 16(7): 2096-2105
Published online Jul 27, 2024. doi: 10.4240/wjgs.v16.i7.2096

Table 1 Baseline information of high albumin-bilirubin group and low albumin-bilirubin group, n (%)

Characteristic	Low ALBI (1908)	High ALBI (2117)	P value
Age, years	60.0 ± 11.6	65.4 ± 12.1	< 0.01^a
Sex			0.096
Male	1098 (57.5)	1273 (60.1)
Female	801 (42.5)	844 (44.2)
BMI, kg/m²	23.1 ± 3.1	22.4 ± 3.3	< 0.01^a
Smoking	707 (37.1)	813 (38.4)	0.378
Drinking	580 (30.4)	650 (30.7)	0.834
Hypertension	475 (24.9)	575 (27.2)	0.102
T2DM	225 (11.8)	273 (12.9)	0.289
CHD	55 (2.9)	117 (5.5)	< 0.01^a
Albumin, g/L	44.3 ± 3.8	36.3 ± 4.1	< 0.01^a
Total bilirubin, μmol/L	10.9 ± 5.4	12.0 ± 6.3	< 0.01^a
ALBI	-3.1 ± 0.3	-2.4 ± 0.3	< 0.01^a
Surgical history	446 (23.4)	500 (23.6)	0.856
Open surgery	163 (8.5)	365 (17.2)	< 0.01^a
Tumor location			< 0.01^a
Colon	1132 (59.3)	1005 (47.5)
Rectum	776 (40.7)	1112 (52.5)
TNM stage			< 0.01^a
I	449 (23.5)	348 (16.4)
II	770 (40.4)	956 (45.2)
III	689 (36.1)	813 (38.4)
Tumor size			< 0.01^a
< 5 cm	1241 (65.0)	1106 (52.2)
≥ 5 cm	667 (35.0)	1011 (47.8)

^aP < 0.05.

ALBI: Albumin-bilirubin; T2DM: Type 2 diabetes mellitus; BMI: Body mass index; CHD: Coronary heart disease.

Table 2 Short-term outcomes in high albumin-bilirubin group and low albumin-bilirubin group

Characteristic	Low ALBI (1908)	High ALBI (2117)	P value
Operation time (min)	223.6 ± 79.6	226.3 ± 81.7	0.295
Intraoperative blood loss (mL)	90.5 ± 122.5	104.4 ± 139.4	0.001^a
Blood transfusion (%)	25 (1.3)	51 (2.4)	0.011
Postoperative hospital stay (d)	10.7 ± 9.4	11.6 ± 8.0	0.001^a
Overall complications (%)	323 (16.9)	557 (26.3)	< 0.01^a
Major complications (%)	32 (1.7)	61 (2.9)	< 0.01^a

^aP < 0.05.

ALBI: Albumin-bilirubin.

Table 3 Univariate and multivariate analysis of overall survival

Risk factor	Univariate analysis		Multivariate analysis
Risk factor	HR (95%CI)	P value	HR (95%CI)	P value
Age (years)	1.045 (1.037-1.053)	< 0.01^a	1.038 (1.030-1.046)	< 0.01^a
Sex (male/female)	0.873 (0.733-1.040)	0.128
BMI (kg/m²)	0.952 (0.926-0.978)	< 0.01^a	0.984 (0.958-1.012)	0.263
T2DM (yes/no)	1.280 (1.002-1.633)	0.048^a	0.981 (0.765-1.259)	0.883
Tumor site (colon/rectum)	1.173 (0.989-1.390)	0.066
Tumor stage (III/II/I)	2.133 (1.864-2.440)	< 0.01^a	2.099 (1.830-2.407)	< 0.01^a
Smoking (yes/no)	1.055 (0.887-1.256)	0.543
Drinking (yes/no)	1.025 (0.852-1.232)	0.796
Hypertension (yes/no)	1.016 (0.836-1.234)	0.874
Tumor size (≥ 5 cm/< 5 cm)	1.464 (1.235-1.736)	< 0.01^a	1.231 (1.037-1.461)	0.017^a
ALBI (high/low)	1.900 (1.587-2.274)	< 0.01^a	1.368 (1.134-1.649)	0.001^a
Overall complications (yes/no)	1.886 (1.580-2.252)	< 0.01^a	1.619 (1.353-1.938)	< 0.01^a

^aP < 0.05.

BMI: Body mass index; T2DM: Type 2 diabetes mellitus, ALBI: Albumin-bilirubin.

Table 4 Univariate and multivariate analysis of disease-free survival

Risk factor	Univariate analysis		Multivariate analysis
Risk factor	HR (95%CI)	P value	HR (95%CI)	P value
Age (years)	1.033 (1.026-1.040)	<0.01^a	1.027 (1.020-1.035)	< 0.01^a
Sex (male/female)	0.885 (0.757-1.035)	0.127
BMI (kg/m²)	0.972 (0.949-0.996)	0.023^a	0.997 (0.973-1.021)	0.777
T2DM (yes/no)	1.129 (0.899-1.418)	0.297
Tumor site (colon/ rectum)	1.095 (0.940-1.276)	0.245
Tumor stage (III/II/I)	2.046 (1.816-2.305)	< 0.01^a	2.020 (1.790-2.280)	< 0.01^a
Smoking (yes/no)	1.037 (0.918-1.255)	0.374
Drinking (yes/no)	1.029 (0.872-1.214)	0.736
Hypertension (yes/no)	1.027 (0.863-1.223)	0.763
Tumor size (≥ 5 cm/< 5 cm)	1.320 (1.133-1.538)	< 0.01^a	1.134 (0.972-1.323)	0.110
ALBI (high/low)	1.585 (1.354-1.855)	< 0.01^a	1.504 (1.276-1.774)	< 0.01^a
Overall complications (yes/no)	1.686 (1.433-1.983)	< 0.01^a	1.241 (1.053-1.463)	0.010^a

^aP < 0.05.

BMI: Body mass index; T2DM: Type 2 diabetes mellitus, ALBI: Albumin-bilirubin.

Table 5 Previous studies reporting the albumin-bilirubin score of colorectal cancer patients

Ref.	Year	Country	Sample size	High ALBI, n (%)	Patients	Outcomes
Zhu et al[26]	2020	China	284	165 (58.1)	CRC	ALBI score was an independent indicator for postoperative complications and OS after radical surgery
Koh et al[27]	2022	South Korea	1015	173 (17.0)	CRC	ALBI score was an independent risk factor for OS in patients after radical CRC patients
Abdel-Rahman[28]	2019	Canada	1434	648 (45.2)	mCRC	ALBI score was an independent risk factor for OS and progression-free survival in CRC patients with liver metastasis after chemotherapy
Watanabe et al[29]	2021	Japan	60	28 (46.7)	CRC	High-ALBI group had shorter OS, and was correlated with shorter time to treatment failure and liver dysfunction in CRC patients treated with regorafenib

CRC: Colorectal cancer; mCRC: Metastatic colorectal cancer; ALBI: Albumin-bilirubin; OS: Overall survival.

Citation: Diao YH, Shu XP, Tan C, Wang LJ, Cheng Y. Preoperative albumin-bilirubin score predicts short-term outcomes and long-term prognosis in colorectal cancer patients undergoing radical surgery. World J Gastrointest Surg 2024; 16(7): 2096-2105
URL: https://www.wjgnet.com/1948-9366/full/v16/i7/2096.htm
DOI: https://dx.doi.org/10.4240/wjgs.v16.i7.2096